BioCentury | Dec 17, 2001
Product Development

Rituxan reaches out

For refractory patients with idiopathic thrombocytopenia purpura (ITP), a disorder characterized by immune-mediated platelet destruction, treatment with Rituxan rituximab represents a new option that generated significant interest at the American Society of Hematology meeting in...
BC Week In Review | Jan 29, 2001
Company News

Cypress, Fresenius HemoCare GmbH sales and marketing update

The companies restructured their 1999 distribution deal to make Fresenius and its Fresenius HemoCare Inc. subsidiary (Redmond, Wash.) exclusive global distributors of CYPB's Prosorba column treatment for rheumatoid arthritis. Formerly, the distributors held exclusive rights...
BC Week In Review | Apr 10, 2000
Company News

Cypress, Fresenius HemoCare GmbH sales and marketing update

CYPB partner Fresenius HemoCare launched in Europe CYPB's Prosorba protein A matrix plasmapheresis column to treat rheumatoid arthritis (RA). Fresenius HemoCare will market the column for use with its Fresenius Cell Separator and Leukocyte Filter...
BC Extra | Apr 7, 2000
Company News

Cypress BioSciences launches Prosorba in Europe

CYPB and partner Fresenius HemoCare (Bad Homburg, Germany) launched in Europe CYPB's Prosorba protein A matrix plasmapheresis column to treat rheumatoid arthritis. The treatment system includes the Fresenius Cell Separator and Leukocyte Filter....
BC Week In Review | Mar 13, 2000
Clinical News

Prosorba Protein A matrix plasmapheresis column regulatory update

Canada granted marketing approval for Prosorba to treat rheumatoid arthritis. Medexus Inc. (Toronto, Ontario) will market the product in Canada. Separately, CYPB said that partner Fresenius HemoCare GmbH (Bad Homburg, Germany) received CE Mark approval...
BC Extra | Mar 9, 2000
Company News

Cypress receives German marketing approval

CYPB said partner Fresenius HemoCare (Bad Homburg, Germany) received the CE Mark for CYPB's Prosorba protein A matrix plasmapheresis column to treat rheumatoid arthritis. The product will be launched in the second quarter....
BC Week In Review | Dec 13, 1999
Company News

Cypress, Medexus Inc. sales and marketing update

Medexus will exclusively distribute CYPB's Prosorba column in Canada and will pay CYPB the lesser of the pre-determined percentage of Prosorba's net sales or a transfer price. Medexus also will conduct a trial in Canada...
BC Week In Review | Oct 18, 1999
Clinical News

Prosorba column: Phase III data; marketed to treat RA and ideopathic thrombocytopenic purpura (ITP)

CYPB published in Arthritis and Rheumatism previously reported data from its 109-patient Phase III study in which 31.9 percent of Prosorba-treated patients showed improvement in American College of Rheumatology (ACR) criteria compared to 11.4 percent...
BC Week In Review | Aug 30, 1999
Clinical News

Prosorba column: Pilot data; marketed to treat RA and ideopathic thrombocytopenic purpura (ITP)

CYPB published in The Journal of Rheumatology data from a pilot study of the column in 15 patients with RA refractory to disease-modifying anti-rheumatic drugs (DMARDs). Patients in the study received Prosorba treatments once a...
BioCentury | Aug 16, 1999
Analyst Picks & Changes

Analyst picks & changes

Cypress Bioscience Inc. (CYPB), San Diego, Calif. Business: Autoimmune/Inflammation First Security Van Kasper analyst Alan Auerbach began coverage with a "strong buy" and a $6 price target. He said that increased awareness of CYPB's approved...
Items per page:
1 - 10 of 74